Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives $39.50 Consensus Target Price from Brokerages

Genmab A/S Sponsored ADR (NASDAQ:GMAB) has received a consensus recommendation of “Moderate Buy” from the eleven analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokerages that have issued ratings on the stock in the last year is $39.75.

A number of analysts have issued reports on GMAB shares. HC Wainwright raised their target price on Genmab A/S from $40.00 to $41.00 and gave the stock a “buy” rating in a research report on Monday. Guggenheim upgraded Genmab A/S from a “neutral” rating to a “buy” rating and set a $43.00 price target for the company in a research note on Tuesday, September 23rd. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Finally, Wall Street Zen lowered shares of Genmab A/S from a “buy” rating to a “hold” rating in a research report on Saturday, November 8th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of GMAB. Osaic Holdings Inc. boosted its stake in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares in the last quarter. Jones Financial Companies Lllp lifted its holdings in Genmab A/S by 29.1% in the third quarter. Jones Financial Companies Lllp now owns 1,951 shares of the company’s stock worth $57,000 after buying an additional 440 shares during the period. Orion Porfolio Solutions LLC boosted its position in Genmab A/S by 2.3% during the 3rd quarter. Orion Porfolio Solutions LLC now owns 19,693 shares of the company’s stock valued at $604,000 after acquiring an additional 441 shares in the last quarter. CWM LLC boosted its position in Genmab A/S by 28.3% during the 3rd quarter. CWM LLC now owns 2,306 shares of the company’s stock valued at $71,000 after acquiring an additional 509 shares in the last quarter. Finally, Captrust Financial Advisors grew its holdings in shares of Genmab A/S by 2.4% during the 2nd quarter. Captrust Financial Advisors now owns 22,442 shares of the company’s stock worth $464,000 after acquiring an additional 526 shares during the period. 7.07% of the stock is currently owned by hedge funds and other institutional investors.

Genmab A/S Stock Up 0.5%

GMAB opened at $30.47 on Monday. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $33.65. The company’s 50-day moving average price is $29.85 and its two-hundred day moving average price is $24.66. The stock has a market cap of $19.56 billion, a price-to-earnings ratio of 12.97, a PEG ratio of 1.58 and a beta of 0.96.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.17. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $975.40 million. Genmab A/S has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Genmab A/S will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.